For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Infinity Pharmaceuticals, Inc.

USPTO Granted Patents = 108

CIPO Patents = 6

EPO Patents = 20

Trademarks = 7

Forward Citations = 1,482

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Alfredo C Castro (63 out of 114 patents)

Martin R Tremblay (38 out of 47 patents)

Catherine Anne Evans (37 out of 44 patents)

4. Michael J Grogan (33 out of 44 patents)

5. Louis Grenier (32 out of 51 patents)

6. Tao Liu (29 out of 38 patents)

7. Daniel A Snyder (29 out of 34 patents)

8. Andre Lescarbeau (28 out of 32 patents)

9. Somarajannair Janardanannair (23 out of 24 patents)

10. Pingda Ren (20 out of 137 patents)

11. Julian Adams (20 out of 42 patents)

12. Brian C Austad (18 out of 31 patents)

13. James R Porter (18 out of 24 patents)

14. Thomas T Tibbitts (17 out of 22 patents)

15. Mark L Behnke (16 out of 28 patents)

Core Competencies:

PI3 Kinase Inhibitors

Heterocyclic Compounds

Isoquinolinones

Cyclopamine Analogs

Combination Therapies

Fatty Acid Amide Hydrolase

Trisubstituted Bicyclic Compounds

Monoacylglycerol Lipase Inhibitors

Enzymatic Transamination

Transfer Hydrogenation

Stereoselective Reduction

Chemical Compounds

108 patents: Sort by Forward Citations

1. 12213983 - Treatment of cancers using PI3 kinase isoform modulators (2025-02-04),

2. 12152032 - Heterocyclic compounds and uses thereof (2024-11-26),

3. 11944631 - Combination therapies (2024-04-02),

4. 11939333 - Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same (2024-03-26),

5. 11602527 - Methods of use of cyclopamine analogs (2023-03-14),

6. 11541059 - Heterocyclic compounds and uses thereof (2023-01-03),

7. 11312718 - Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (2022-04-26),

8. 11247995 - Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same (2022-02-15),

9. 11147818 - Combination therapies (2021-10-19),

10. 11110096 - Combination therapies (2021-09-07),

11. 11007181 - Cyclopamine analogs (2021-05-18),

12. 10941162 - Heterocyclic compounds and uses thereof (2021-03-09),

13. 10919914 - Heterocyclic compounds and uses thereof (2021-02-16),

14. 10821102 - Methods of use of cyclopamine analogs (2020-11-03),

15. 10759806 - Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors (2020-09-01),

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines for the treatment of cancer and other challenging diseases. With a focus on targeted therapies, Infinity aims to create novel drugs that deliver meaningful benefits to patients. Through its research and development efforts, the company discovers and develops potential drug candidates, advancing them through clinical trials and regulatory approval processes. Infinity Pharmaceuticals strives to improve the lives of patients worldwide by transforming scientific discoveries into life-changing treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

108 Patents

#26 in Cambridge, MA

#191 in Massachusetts

#3,407 in US

#7,068 in the World

Cambridge, MA, United States of America

Infinity Pharmaceuticals, Inc.

Forward Citations = 1,482

78 inventors:

Alfredo C Castro (63 out of 114 patents)

Martin R Tremblay (38 out of 47 patents)

Catherine Anne Evans (37 out of 44 patents)

4. Michael J Grogan (33 out of 44 patents)

5. Louis Grenier (32 out of 51 patents)

Please report any incorrect information to support@idiyas.com

Loading…